Viking Therapeutics, Inc. (VKTX)
Pre-market:
| Previous close | 62.75 |
| Open | 63.50 |
| Bid | 65.38 x 600 |
| Ask | 65.46 x 300 |
| Day's range | 62.33 - 65.90 |
| 52-week range | 8.28 - 99.41 |
| Volume | |
| Avg. volume | 4,585,686 |
| Market cap | 7.207B |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.96 |
| Earnings date | 24 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 113.90 |
ZacksWall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Insider MonkeyThis Biotech Stock is a “Strong Buy” According to Raymond James
We recently compiled a list of the 7 Best Mid-Cap Healthcare Stocks To Buy Now and in this article we will look at a particular biotech which recently got a “Strong Buy” rating from Raymond James analysts. Challenges in the Health Sector The healthcare industry is considered to be a fairly defensive sector due to […]
BloombergWeight-Loss Upstart Viking Needs a Deal to Vie With Lilly and Novo
(Bloomberg) -- Hope for a weight-loss drug that’s better than Ozempic and Wegovy has sent Viking Therapeutics Inc. shares skyrocketing. But to reach the next level the biopharmaceutical developer likely needs a partner — or a buyer.Most Read from BloombergThese Flight Routes Suffer the World’s Worst TurbulenceOne Dead After Singapore Air Flight Hit By Severe TurbulenceCiti Trader Got 711 Warning Messages Before Sparking Flash Crash‘It Felt Like We Had Crashed’: Singapore Air Passenger Describes
